TY - JOUR
T1 - Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma
AU - Manini, Matteo Angelo
AU - Sangiovanni, Angelo
AU - Fornari, Fabio
AU - Piscaglia, Fabio
AU - Biolato, Marco
AU - Fanigliulo, Libera
AU - Ravaldi, Elisa
AU - Grieco, Antonio
AU - Colombo, Massimo
PY - 2014
Y1 - 2014
N2 - Background & Aims Although contrast-enhanced computed tomography (CT), dynamic magnetic resonance (MRI) and fine needle biopsy (FNB) are the standard of care to diagnose hepatocellular carcinoma (HCC), the clinical and economic benefits of the updated AASLD diagnostic algorithm, including the drop of contrast enhanced ultrasound (CEUS), have not been previously evaluated. Methods 119 de novo liver nodules detected during ultrasound (US) surveillance in 98 cirrhotics, 7 2 cm in size, were sequentially examined by CEUS and CT, using MRI as a rescue approach in patients lacking a typical vascular pattern for HCC by one or both contrast techniques in the 1-2 cm nodules and by CT in the >2 cm nodules. A FNB was performed when required to meet both 2005 and 2010 AASLD criteria. Results Eighty-four (70%) nodules were HCC: the radiological diagnosis was done in 38 (88%) of those 1-2 cm and in 38 (95%) for those >2 cm HCCs according to 2010 AASLD criteria. CT or MRI detected 13 HCC nodules that were missed by unenhanced US. Despite an absolute specificity, CEUS failed to identify any HCC uncharacterized by CT or MRI. By updated AASLD criteria, 6 (17%) FNB procedures were spared in patients with 1-2 cm nodules (p = 0.025), as compared to 2005 criteria. The 2010 vs. 2005 AASLD per patient cost was similar in 1-2 cm nodules, 432 € vs. 451 € (p = 0.46), but lower in >2 cm nodules, 248 € vs. 321 € (p
AB - Background & Aims Although contrast-enhanced computed tomography (CT), dynamic magnetic resonance (MRI) and fine needle biopsy (FNB) are the standard of care to diagnose hepatocellular carcinoma (HCC), the clinical and economic benefits of the updated AASLD diagnostic algorithm, including the drop of contrast enhanced ultrasound (CEUS), have not been previously evaluated. Methods 119 de novo liver nodules detected during ultrasound (US) surveillance in 98 cirrhotics, 7 2 cm in size, were sequentially examined by CEUS and CT, using MRI as a rescue approach in patients lacking a typical vascular pattern for HCC by one or both contrast techniques in the 1-2 cm nodules and by CT in the >2 cm nodules. A FNB was performed when required to meet both 2005 and 2010 AASLD criteria. Results Eighty-four (70%) nodules were HCC: the radiological diagnosis was done in 38 (88%) of those 1-2 cm and in 38 (95%) for those >2 cm HCCs according to 2010 AASLD criteria. CT or MRI detected 13 HCC nodules that were missed by unenhanced US. Despite an absolute specificity, CEUS failed to identify any HCC uncharacterized by CT or MRI. By updated AASLD criteria, 6 (17%) FNB procedures were spared in patients with 1-2 cm nodules (p = 0.025), as compared to 2005 criteria. The 2010 vs. 2005 AASLD per patient cost was similar in 1-2 cm nodules, 432 € vs. 451 € (p = 0.46), but lower in >2 cm nodules, 248 € vs. 321 € (p
KW - Cirrhosis
KW - Clinical guidelines
KW - Hepatocellular carcinoma
KW - Imaging techniques
KW - Surveillance
UR - http://www.scopus.com/inward/record.url?scp=84898833685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898833685&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2014.01.006
DO - 10.1016/j.jhep.2014.01.006
M3 - Article
C2 - 24462368
AN - SCOPUS:84898833685
VL - 60
SP - 995
EP - 1001
JO - Journal of Hepatology
JF - Journal of Hepatology
SN - 0168-8278
IS - 5
ER -